Innovations in targeted therapies for triple negative breast cancer

被引:3
作者
McCann, Kelly E. [1 ]
Hurvitz, Sara A. [1 ]
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol Oncol, 2336 Santa Monica Blvd,Suite 304, Los Angeles, CA 90404 USA
关键词
ipatasertib; olaparib; sacituzumab govitecan; talazoparib; triple negative breast cancer; GERMLINE BRCA MUTATION; SACITUZUMAB GOVITECAN; AKT INHIBITOR; DOUBLE-BLIND; PARP; CHEMOTHERAPY; PLUS; NEOADJUVANT; OVARIAN; IMMUNOTHERAPY;
D O I
10.1097/GCO.0000000000000671
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Purpose of review Triple negative breast cancer (TNBC) is defined by a lack of targets, namely hormone receptor (HR) expression and human epidermal growth factor receptor 2 amplification. Cytotoxic chemotherapy remains the mainstay of treatment. Though TNBC constitutes approximately 10-15% of breast cancer, it is disproportionally lethal, but it is hoped that outcomes will improve as targetable oncogenic drivers are identified. Recent findings Translational work in TNBC has focused on subsets defined by defects in homologous recombination repair, immune cell infiltration, or programmed death ligand receptor 1 expression, an over-active phosphoinositide-3 kinase pathway, or expression of androgen receptors. Though not specific to TNBC, the novel cell surface antigen trophoblast antigen 2 has also been identified and successfully targeted. This work has led to Food and Drug Administration approvals for small molecule poly-ADP-ribosyl polymerase inhibitors in patients with deleterious germline mutations in BRCA1 or BRCA2, the combination of nab-paclitaxel with immune checkpoint inhibitor antibodies in the first-line metastatic setting for programmed death ligand receptor 1+ TNBC, and use of the antibody-drug conjugate sacituzumab govitecan in the later-line metastatic setting. Identification of targetable oncogenic drivers in TNBC is an area of intense cancer biology research, hopefully translating to new therapies and improved outcomes.
引用
收藏
页码:34 / 47
页数:14
相关论文
共 50 条
[41]   Advanced Triple-Negative Breast Cancer [J].
Patel, Grisma ;
Prince, Alison ;
Harries, Mark .
SEMINARS IN ONCOLOGY NURSING, 2024, 40 (01)
[42]   Divide and Conquer-Targeted Therapy for Triple-Negative Breast Cancer [J].
Nedeljkovic, Milica ;
Vuletic, Ana ;
Martinovic, Katarina Mirjacic .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (04)
[43]   Targeted Treatment of Metastatic Triple-Negative Breast Cancer: A Systematic Review [J].
Madsen, Anna Martha Hammershoi ;
Eefsen, Rikke Helene Lovendahl ;
Nielsen, Dorte ;
Kumler, Iben .
BREAST JOURNAL, 2024, 2024
[44]   Targeted Therapeutic Strategies for Triple-Negative Breast Cancer [J].
Li, Ying ;
Zhan, Zhijun ;
Yin, Xuemin ;
Fu, Shujun ;
Deng, Xiyun .
FRONTIERS IN ONCOLOGY, 2021, 11
[45]   Triple-negative breast cancer and the potential for targeted therapy [J].
Jhan, Jing-Ru ;
Andrechek, Eran R. .
PHARMACOGENOMICS, 2017, 18 (17) :1595-1609
[46]   Current Therapeutic Strategies for Metastatic Triple-Negative Breast Cancer: From Pharmacists' Perspective [J].
Li, Shuanghe ;
Bao, Chongyang ;
Huang, Lingli ;
Wei, Ji-Fu .
JOURNAL OF CLINICAL MEDICINE, 2022, 11 (20)
[47]   Emerging treatment strategies for metastatic triple-negative breast cancer [J].
Huppert, Laura A. ;
Gumusay, Ozge ;
Rugo, Hope S. .
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
[48]   Hope and Hype around Immunotherapy in Triple-Negative Breast Cancer [J].
Jacobs, Flavia ;
Agostinetto, Elisa ;
Miggiano, Chiara ;
De Sanctis, Rita ;
Zambelli, Alberto ;
Santoro, Armando .
CANCERS, 2023, 15 (11)
[49]   Personalised Therapies for Metastatic Triple-Negative Breast Cancer: When Target Is Not Everything [J].
Capici, Serena ;
Ammoni, Luca Carlofrancesco ;
Meli, Nicole ;
Cogliati, Viola ;
Pepe, Francesca Fulvia ;
Piazza, Francesca ;
Cazzaniga, Marina Elena .
CANCERS, 2022, 14 (15)
[50]   Pathological changes in GPCR signal organisation: Opportunities for targeted therapies for triple negative breast cancer [J].
Lam, Terrance ;
Mastos, Chantel ;
Sloan, Erica K. ;
Halls, Michelle L. .
PHARMACOLOGY & THERAPEUTICS, 2023, 241